Revenue and Profit Growth - Revenue for Q1 2024 increased by 7.76% to 375,491,442.27 yuan compared to the same period last year[5] - Net profit attributable to shareholders rose by 19.03% to 12,359,662.56 yuan year-over-year[5] - Net profit after deducting non-recurring gains and losses surged by 51.52% to 9,658,288.80 yuan[5] - Total operating revenue for the quarter was 375,491,442.27 yuan, an increase from 348,436,396.10 yuan in the same period last year[49] - Net profit attributable to the parent company's owners was 12,359,662.56 yuan, compared to 10,383,267.51 yuan in the previous year[50] R&D and Development Expenditure - Development expenditure increased by 199.14% due to capitalized R&D investments[7] - Development expenditure increased significantly to 51,527,042.13 yuan from 17,224,899.15 yuan, indicating increased investment in R&D[45] Taxes and Other Income - Taxes and surcharges grew by 71.24% due to increased revenue and reduced VAT input tax[7] - Other income decreased by 75.84% due to reduced VAT refunds[8] - Tax refunds received declined by 79.12% year-over-year[23] Cash Flow and Financial Activities - Cash received from investment recovery dropped by 41.32% compared to the previous year[9] - Net cash flow from operating activities was -200,644,939.83, a decrease of 7.52% compared to the previous year[36] - Net cash flow from investing activities was -84,283,588.85, an improvement of 22.16% compared to the previous year[36] - Net cash flow from financing activities was -67,352.65, a significant improvement from -100,000,000.00 in the previous year[36] - Cash received from other investment activities decreased by 42.11% year-over-year, mainly due to reduced purchase and redemption of wealth management products[39] - Cash paid for debt repayment decreased by 100,000,000 year-over-year, mainly due to no bank loan repayment occurring in the current period[39] - Operating cash inflow was 270,290,454.38 yuan, compared to 259,880,225.83 yuan in the same period last year[50] Financial Expenses and Income - Financial expenses decreased by 5,619,400 yuan due to increased interest income[22] - Financial expenses showed a net income of 10,848,488.25 yuan, primarily due to interest income of 11,134,456.08 yuan[49] Investment and Fair Value Changes - Investment income decreased by 161.80% year-over-year, mainly due to reduced investment income from associates[39] - Fair value change income increased by 1,369,100 year-over-year, mainly due to the increase in fair value of other non-current financial assets[39] - Asset impairment loss increased by 2,075,200 year-over-year, mainly due to increased provision for contract asset impairment[39] Assets and Liabilities - Total assets decreased from 5,790,350,720.78 to 5,663,734,821.97, a decline of 2.19%[31] - Total liabilities decreased from 1,126,467,178.33 to 978,024,354.93, a decline of 13.16%[31] - Total assets at the end of the quarter were 5,663,734,821.97 yuan, a decrease from 5,790,350,720.78 yuan at the beginning of the period[49] - Cash and cash equivalents decreased to 806,579,209.32 yuan from 1,094,386,640.73 yuan at the beginning of the period[45] - Accounts receivable increased to 1,708,390,778.27 yuan from 1,579,674,434.61 yuan at the beginning of the period[45] - Total equity attributable to the parent company's owners was 4,625,908,290.50 yuan, slightly up from 4,605,980,419.11 yuan at the beginning of the period[49] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period is 37,506[41] - Ge Hang holds 14.24% of the shares, totaling 220,519,182 shares, with 165,389,386 shares under restricted conditions[41] - Philips (China) Investment Co., Ltd. holds 10.01% of the shares, totaling 155,003,087 shares, all of which are unrestricted[41] - Zhejiang Xinsu Technology Co., Ltd. holds 2.50% of the shares, totaling 38,743,590 shares, all of which are unrestricted[41] - China Bank - Huabao CSI Medical ETF holds 2.33% of the shares, totaling 36,018,329 shares, all of which are unrestricted[41] - Hong Kong Securities Clearing Company Ltd. holds 1.93% of the shares, totaling 29,822,830 shares, all of which are unrestricted[41] - Zhang Lüzheng holds 1.88% of the shares, totaling 29,173,538 shares, with 21,880,153 shares under restricted conditions[41] - China Industrial and Commercial Bank - Caitong Asset Management Value Growth Mixed Fund holds 1.48% of the shares, totaling 22,877,306 shares, all of which are unrestricted[41] - Basic Pension Insurance Fund 1205 Portfolio holds 1.00% of the shares, totaling 15,425,640 shares, all of which are unrestricted[41] - China Construction Bank - China Merchants Flexible Allocation Mixed Fund holds 0.97% of the shares, totaling 15,000,000 shares, all of which are unrestricted[41] Earnings Per Share and Accounting Standards - Basic earnings per share remained stable at 0.01 yuan, consistent with the previous year[50] - The company will implement new accounting standards starting from 2024, which will affect the initial financial statements for the year[52] - The audit report has been reviewed and approved by the Board of Directors of Chuangye Huikang Technology Co., Ltd[52] Accounts Receivable and Financing - Accounts receivable financing increased by 69.95% due to higher bank acceptance bills[21]

1、本次计提信用减值准备和资产减值准备的原因 证券代码：300451 证券简称：创业慧康 公告编号: 2024-023 创业慧康科技股份有限公司 关于 2024 年第一季度计提信用减值准备和资产减值准备 的公告 本公司及董事会全体成员保证公告的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 创业慧康科技股份有限公司（以下简称"公司"）根据《深圳证券交易所上 市公司自律监管指引第 2 号——创业板上市公司规范运作》《企业会计准则》以 及公司相关会计政策的规定，在 2024 年第一季度计提了信用减值损失及资产减 值损失，现将具体情况公告如下： 一、本次计提信用减值准备和资产减值准备情况概述 | 项 目 | 确定组合的依据 | 计量预期信用损失的方法 | | --- | --- | --- | | 其他应收款——应收利息组合 其他应收款——应收股利组合 | 款项性质 | 参考历史信用损失经验， 结合当前状况以及对未来 经济状况的预测，通过违 | | | | 约风险敞口和未来12个月 | | 其他应收款——应收合并范围内 | | 内或整个存续期预期信用 | | 关联方组合 | | 损失率，计算预期信用损 ...

证 券 研 究 报 告 收入稳增长，Hi-HIS 迈向推广新阶段 目标价：4.50 元 2024 年 4 月 13 日，公司发布 2023 年年报：实现营业收入 16.16 亿元，同比增 长 5.81%；归母净利润 0.37 亿元，同比下滑 13.93%；归母扣非净利润 0.34 亿 元，同比下滑 27.44%。 评论： | --- | --- | --- | --- | --- | |---------------------|--------|--------|-------|-------| | | 2023A | 2024E | 2025E | 2026E | | 主营收入 ( 百万 ) | 1,616 | 1,898 | 2,252 | 2,683 | | 同比增速 (%) | 5.8% | 17.5% | 18.6% | 19.1% | | 归母净利润 ( 百万 ) | 37 | 161 | 227 | 309 | | 同比增速 (%) | -14.0% | 338.3% | 40.9% | 36.3% | | 每股盈利 ( 元 ) | 0.02 | 0.10 | 0.15 | 0.20 | | ...

多方位巩固龙头优势，盈利能力有望修复 | --- | --- | --- | --- | --- | |-------------------------------------------------------|---------------|----------------|----------------|----------------| | | | | | | | [Table_MainProfit] 指标 / 年度 营业收入（百万元） | 2023A | 2024E | 2025E | 2026E | | 增长率 | 1615.87 5.81% | 1867.72 15.59% | 2220.93 18.91% | 2648.48 19.25% | | 归属母公司净利润（百万元） | 36.69 | 202.17 | 277.08 | 390.26 | | 增长率 | -13.95% | 451.05% | 37.05% | 40.84% | | 每股收益 EPS （元） | 0.02 | 0.13 | 0.18 | 0.25 | | 净资产收益率 ROE | 0.98% | 5.12% | 6 ...

Investment Rating - The report assigns a "Buy" rating for the company, indicating a positive outlook based on expected performance relative to market indices [23]. Core Insights - In 2023, the company achieved revenue of 1.616 billion yuan, a year-on-year increase of 5.81%, while the net profit attributable to shareholders decreased by 13.93% to 37 million yuan [2]. - The company has secured 29 software orders exceeding 10 million yuan each, totaling nearly 500 million yuan, indicating a robust demand in the healthcare information technology sector [2]. - The partnership with Philips is expected to enhance product offerings and drive growth, particularly in AI applications within healthcare [3][18]. Financial Performance Summary - Revenue for 2023 was 1.616 billion yuan, with a gross margin of 46.98%, down 2.41 percentage points year-on-year [2]. - The company forecasts revenues of 1.888 billion yuan, 2.249 billion yuan, and 2.642 billion yuan for 2024, 2025, and 2026, respectively, with growth rates of 16.84%, 19.11%, and 17.50% [3][19]. - The net profit is projected to rebound significantly, reaching 222 million yuan in 2024, reflecting a growth rate of 505.58% [3][19]. Operational Developments - The Hi-HIS system has been implemented in over 40 hospitals, with a significant portion being tertiary hospitals, showcasing the company's expanding footprint in the healthcare sector [9]. - The company has made necessary personnel preparations to handle the increasing order volume, although this has led to higher operational costs [2]. Market Position and Future Outlook - The strategic collaboration with Philips is anticipated to create synergies in product development and market reach, positioning the company favorably in the healthcare IT landscape [3][18]. - The report suggests maintaining attention on the company due to its focus on healthcare information technology and the expected recovery in industry demand [3].

业绩简评 客户结构持续优化，医保业务增长明显。分产品来看，公司软件 销售实现营收 6.83 亿元，同比增长 20.18%，主要系 Hi-HIS 等系 统打磨成熟，同时客户结构持续优化所致，2023 年公司新老客户 占比分别为 37%、63%。公司 2023 年在智慧医院和公共卫生领 域获得千万级以上软件订单 29 个，总金额近 5 亿元。公司 Hi-HIS 产品处于推广期，全年新签订单 22 个，订单金额同比大幅提升， 目前该系统已在全国 40 余家医院客户实施应用。分业务来看，公 司智慧医保相关系统销售额同比提升 204.58%，其中 DRG/DIP 产品线的合同数同比增长 217.39%，回款额同比增长 463.43%， 主要系国家医保局发布的《DRG/DIP 支付方式改革三年行动计划》 稳步推进，公司医保局端项目已覆盖全国 22 个三级医院和 77 家 二级及以下医疗机构。 风险提示 创业慧康 (300451.SZ) 经营分析 盈利预测 医疗信息化政策推进不及预期的风险；医药反腐对招标产生的不 确定性影响；与飞利浦协同不及预期的风险；市场竞争加剧的风 险；大股东质押风险；应收账款和存货偏高的风险。 市价 ...

Health Solutions and Services - The company has established a comprehensive smart health solution to support regional health information service systems, focusing on achieving full population coverage and integrated health information services[1]. - The company has been awarded a 10-year franchise by the health bureau of a city in Guangdong province to operate a health service platform, integrating various health services and promoting the city's health industry development[5]. - The company is participating in health city construction in a city in Zhejiang province, aiming to enhance medical service efficiency and promote equal access to healthcare services[5]. - The company has implemented a new service model that integrates medical and elderly care services, enhancing community support for the elderly[5]. - The company has developed a community health service information system in a provincial capital city, standardizing electronic health records for residents[3]. - The company has upgraded the information technology of a nursing home in Suzhou, integrating internet and IoT services to improve management and care quality[3]. - The "Health Wenzhou" platform achieved over 1 million user connections and covered 310 medical institutions, while "Health Zhongshan" registered 3.14 million users[44]. Technology and Innovation - The company has formed a strategic partnership with Zhejiang University to advance AI technology in clinical medicine and public health[11]. - The company has launched the CareSync electronic medical record product in collaboration with Philips, designed to meet the needs of various healthcare service providers[14]. - The company has achieved a four-level or above rating for interconnectivity with 39 clients, facilitating data sharing among healthcare institutions[13]. - The company has completed multiple projects aimed at enhancing emergency medical processes and integrating AI technologies into healthcare services, achieving all technical indicators[33]. - The company’s smart medical assistant has been successfully implemented in the Zhejiang University Medical College Affiliated Obstetrics and Gynecology Hospital[19]. - The company is actively participating in industry forums and standard-setting for medical IoT, reinforcing its position as a leading enterprise in the sector[16]. - The company is focusing on the integration of AI into healthcare, developing a unified platform that aggregates various AI applications to provide customized solutions for clients[114]. - The company is developing a smart medical imaging big data analysis platform to improve diagnostic accuracy and reduce costs for patients[74]. Financial Performance and Investments - As of the end of the reporting period, the new smart medical insurance business has covered 13 provinces and 11 cities, with sales increasing by 204.58% year-on-year in 2023; the DRG/DIP product line saw contract numbers rise by 217.39% and collection amounts by 463.43%[17]. - Research and development investment reached ¥339,476,026.88 in 2023, accounting for 21.01% of total revenue, an increase from 20.83% in 2022[34]. - The company reported a revenue growth of 15% year-over-year for the fiscal year 2023, reaching a total of 1.2 billion RMB[200]. - The company has a remaining balance of ¥24.52 million in raised funds as of December 31, 2023, which will be transferred to the company's basic settlement account for working capital[75]. - The total investment amount for the reporting period was ¥386,482,666.01, a decrease of 29.14% compared to ¥545,387,398.25 in the same period last year[85]. - The company reported a significant increase in trading financial assets, with a fair value change of ¥42,378.08 and a purchase amount of ¥117,100,000.00 during the reporting period[65]. - The company plans to distribute a cash dividend of 0.1 yuan per 10 shares (including tax) to all shareholders, with no bonus shares issued[161]. Market Strategy and Growth - The company is expanding its innovative business segments and exploring sustainable development in its operations[14]. - The company is actively responding to new economic and industrial conditions by promoting new product development and technological innovation while expanding its market reach and national sales network[177]. - The company aims to strengthen its market position and enhance its core competitiveness by broadening its product line and health service ecosystem to improve profitability[178]. - The company is focusing on expanding its market presence and adjusting product development strategies based on user demand and market competition, while maintaining robust financial controls[154]. - The company is exploring potential acquisitions to enhance its service offerings, with a budget of 200 million RMB allocated for this purpose[200]. - Market expansion plans include entering three new provinces in China, targeting a 10% market share in these regions by 2025[200]. Challenges and Risks - In 2023, the company faced increased personnel costs and implementation expenses due to rapid order growth, leading to a decline in profit performance[40]. - The company acknowledges the uncertainty in its operations due to potential changes in national policy and macroeconomic conditions that could affect the healthcare information technology sector[195]. - The company faces risks related to market competition and potential resource shortages that could impact its market expansion plans[169]. - The company is actively managing risks related to external acquisitions and the potential impairment of goodwill due to changes in the macroeconomic environment[159]. - The company is implementing measures to balance project implementation and improve cash collection processes to mitigate seasonal operational risks[157]. Research and Development - The number of R&D personnel constitutes 35.54% of the workforce, reflecting a slight decrease from 36.20%[30]. - The company aims to enhance its R&D efforts by collaborating with renowned universities and research institutions to develop new products, addressing the risks associated with technology and product development[152]. - The company plans to enhance its R&D investment and closely monitor industry trends and innovations to maintain its core competitive advantages in user numbers and technology[172]. - The company is committed to enhancing its talent management strategies to retain high-level technical and managerial talent, ensuring stability and productivity within its core team[128]. Future Outlook - The company has provided a revenue guidance of 1.5 billion RMB for the next fiscal year, representing a projected growth of 25%[200]. - New product launches are expected to contribute an additional 300 million RMB in revenue in 2024[200]. - The company anticipates a gradual recovery in the healthcare informationization industry despite facing challenges in 2023[40]. - The company aims to transition from an IT information product service company to a technology cloud ecosystem enterprise, following the "Health China 2030" plan and the "HDAI" strategy for integrated medical and health intelligent product development[110].

证券代码：300451 证券简称：创业慧康 公告编号：2024-018 创业慧康科技股份有限公司 第八届监事会第四次会议决议公告 本公司及监事会全体成员保证公告的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 创业慧康科技股份有限公司（以下简称"公司"或"本公司"）第八届监事 会第四次会议的通知于 2024 年 4 月 2 日以邮件、传真等方式向各位监事发出， 并于 2024 年 4 月 12 日在公司二楼会议室以现场会议的方式召开。会议应到监事 3 名，实到监事 3 名。会议的召开及表决符合《中华人民共和国公司法》《创业 慧康科技股份有限公司章程》等有关规定。 经表决，形成如下决议： 一、审议通过了《关于<2023 年度监事会工作报告>的议案》 本议案尚需提交 2023 年年度股东大会审议。 二、审议通过了《关于<2023 年年度报告及摘要>的议案》 经审核，监事会认为：董事会编制和审核公司 2023 年年度报告的程序符合 法律、法规和中国证监会的有关规定，报告内容真实、准确、完整地反映了公司 2023 年度经营的实际情况，不存在任何虚假记载、误导性陈述或者重大遗漏。 具体内容详见同日刊登在中 ...

证券代码：300451 证券简称：创业慧康 公告编号：2024-021 创业慧康科技股份有限公司 关于举行 2023 年度业绩网上说明会的公告 本公司及董事会全体成员保证公告的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 创业慧康科技股份有限公司（以下简称"公司"）已于 2024 年 4 月 13 日在 巨潮资讯网披露了《2023 年年度报告》及《2023 年年度报告摘要》。为便于广 大投资者更加全面深入地了解公司经营业绩、发展战略等情况，公司定于 2024 年 4 月 24 日（星期三）15:00-17:00 在"价值在线"（www.ir-online.cn）举办 2023 年度业绩网上说明会，与投资者进行沟通和交流，广泛听取投资者的意见和建议。 一、说明会召开的时间、地点和方式 二、参加人员 三、投资者参加方式 投 资 者 可 于 2024 年 4 月 24 日 （ 星 期 三 ） 15:00-17:00 通过网址 https://eseb.cn/1dyNHzGTAvC或使用微信扫一扫以下小程序码即可进入参与互动 交流。投资者可于 2024 年 4 月 24 日前进行访问，打开互动交流进行 ...

股票简称:创业慧康 作 门 股票代码: 300451.SZ 创造智慧医卫 服务健康事业 电话:0571-88217878 传真:0571-88217703 地址：杭州市滨江区越达巷 92 号创业智慧大厦 创业慧康微信公众号 2023年度可持续发展报告 暨环境、社会及公司治理(ESG)报告 Environmental,Social&Governance (ESG ) Report 2023 = 灵 | 01 | 02 | 03 | 04 | 05 | | --- | --- | --- | --- | --- | | 董事长致辞 | 关于创业慧康 | 数说2023 | 可持续发展管理战略 | 专题故事: | | | | | | 科技师科 | | 06 | 07 | 08 | 00 | 10 | | --- | --- | --- | --- | --- | | 公司治理 | 产品与服务 | 合规与安全 | 人才与可持续职场 | 社会责任 | | 公司治理框架 | 产品质量与安全 | 合规运营 | 人才引进 | 党建与工会 | | 商业道德 | 客户服务 | 信息安全与数据运营 | 人才激励与留存 | 产学研合作 ...